SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) OCTOBER 23, 2002
----------------
CEPHALON, INC.
--------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-19119 23-2484489
- --------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
145 Brandywine Parkway
West Chester, Pennsylvania 19380
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (610) 344-0200
--------------
NOT APPLICABLE
------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
On October 23, 2002, Cephalon, Inc. (the "Registrant"), publicly announced
results of its clinical study evaluating PROVIGIL(R) (modafinil) C-IV in
patients with shift work sleep disorder.
The Registrant hereby incorporates by reference the press release dated October
23, 2002 attached hereto as Exhibit 99.1, and made a part of this Item 5.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(a) FINANCIAL STATEMENTS OF BUSINESS ACQUIRED: None
(b) PRO FORMA FINANCIAL INFORMATION: None
(c) EXHIBITS
NUMBER DESCRIPTION
------ ------------
99.1 Press Release - Cephalon Announces Positive Results of
ROVIGIL Clinical Study in Shift Work Sleep Disorder
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CEPHALON, INC.
Date: October 30, 2002 By: /s/ JOHN E. OSBORN
------------------------------------
John E. Osborn
Senior Vice President and General Counsel
EXHIBIT INDEX
Exhibit
NUMBER DESCRIPTION
------- -----------
99.1 Press Release - Cephalon Announces Positive Results of PROVIGIL
Clinical Study in Shift Work Sleep Disorder